[Letter to shareholders] [FR] Numéro Avril 2020

21/04/20

DOWNLOAD

[Webinar] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

[Webinar] [EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

View the presentation on line [Webinar] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

Akanksha Gangar, PhD, Study Director
28 April 2020
05:00 PM-05:45 PM - CEST


Immunological cell death (ICD) is a form of cancer cell death induced by radiotherapy, photodynamic therapy and chemotherapeutic agents.
Unlike apoptosis or necrosis, ICD can induce an effective immune response directed against the tumor whereby both dendritic cells and T lymphocytes are mediators of this response. Dying cancer cells recruit and activate immune cells by releasing damage-associated molecular patterns (DAMPs).

Using our in-house developed screening strategy facilitated by an in vitro platform with four assays, we have identified and characterized several ICD inducers and a Nanocyclix compound for the three key DAMPs and cell viability in several cell lines. Evaluation of phagocytosis and cytokine levels showed that ICD activates both innate and adaptive arms of the immune system. With respect to cancer immunotherapy, the ICD process elicits enhanced adjuvanticity and antigenicity from dying cancer cells and consequently, promotes the development of clinically desired antitumor immunity.

In essence, we describe a novel strategy for the identification of ICD inducers within large chemical libraries followed by ex-vivo co-culture assays to demonstrate enhanced DC and T cell function. 

Key learning objectives 

  • Introduction to ICD
  • How Oncodesign can help you to identify / characterize ICD inducers in vitro, ex vivo and in vivo
  • Case study  

About our speaker Akanksha Gangar 

Akanksha Gangar obtained her PhD in Biochemistry from the prestigious Indian Institute of Science. She then continued as a postdoctoral research associate at the University of North Carolina at Chapel Hill to study cell polarity. In 2005, Akanksha joined INSERM, France as a Research Scientist to work on cell polarity in an oncological context. She joined GSK, France in 2007 to support their drug development in hypertension, diabetes, obesity and oncology. In 2016, Akanksha joined Oncodesign’s in vitro department as a Study director focusing on cancer related projects.

 

 

%MCEPASTEBIN%

View the presentation on line

 

[Press Release] Very strong improvement in full-year 2019 results

09/04/20

DOWNLOAD

Business Continuity Plan – COVID-19

Banner Business Continuity Plan – Covid-19

In the current context of the COVID-19 Coronavirus pandemic, we wanted to inform you of the measures taken by the company to ensure the continuity of its business.

Oncodesign activated its "Pandemic Crisis Management Plan" on March 12, 2020 which covers the whole company, our laboratories, quality services, IT infrastructure, human resources and logistics in order to guarantee the implementation of our services, in compliance with any additional instructions that the health authorities may decide.

Preventive measures have already been implemented to protect our employees and to adapt work organization.

I read the measures